Ferric carboxymaltose · Injectafer / Ferinject

Other

Approvedregulatory verdict

Evidence outlook

Approved: Heart Failure, Chronic Kidney Disease, Iron Deficiency Anemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
CA
  • FERINJECT (ferric carboxymaltose) is indicated: • for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older when oral iron preparations are not tolerated or are ineffective. • for the treatment of iron deficiency (ID) in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity. The diagnosis of iron deficiency must be based on laboratory tests.
Product first approved 2024Health Canada
Featured evidence outside this drug's tracked markets:NCT00396292 · Anemia · Phase 3 · completed · Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (45)
Chronic Kidney Disease
NCT00994318 · Vifor Pharma
2009-12 – 2014-02 · Iron Deficiency Anaemia, Chronic Kidney Disease
What this study did
NCT00548691 · American Regent, Inc.
2007-10 – 2009-07 · Anemia
What this study did
NCT00317226 · American Regent, Inc.
2005-06 – 2007-09 · Anemia
What this study did
Heart Failure
NCT03833336 · Institut de Recerca Biomèdica de Lleida
2017-08-23 – 2024-12-20 · Heart Failure With Normal Ejection Fraction, Ferropenic Anemia
What this study did
NCT03991000 · Dr. med. Mahir Karakas
2019-02-28 – 2021-12-15 · Cardiovascular Diseases, Anemia, Iron-deficiency, Acute Myocardial Infarction, Atrial Fibrillation, Systolic Heart Failure
What this study did
NCT01394562 · Vifor Pharma
2011-07 – 2016-05 · Iron Deficiency, Chronic Heart Failure
What this study did
Iron Deficiency Anemia
NCT05590260 · NICHD Global Network for Women's and Children's Health
2023-05-30 – 2025-07-28 · Postpartum Anemia
What this study did
NCT04976179 · University of Lagos, Nigeria
2021-08-09 – 2023-06-15 · Iron Deficiency Anemia of Pregnancy
What this study did
NCT03523117 · American Regent, Inc.
2019-01-31 – 2021-01-29 · Iron Deficiency Anemia
What this study did
NCT03591406 · Vifor (International) Inc.
2017-07-03 – 2019-02-25 · Iron Deficiency Anemia
What this study did
NCT02541708 · Ifakara Health Institute
2015-09 – 2018-04 · Iron-Deficiency Anemia
What this study did
NCT01837082 · University of Ulm
2013-04 – 2015-12 · Heart Failure, Iron Deficiency, Anemia
What this study did
NCT01101399 · Vifor Pharma
2010-05 – 2013-11 · Iron-Deficiency Anemia
What this study did
NCT00703937 · American Regent, Inc.
2008-07 – 2011-03 · Anemia
What this study did
NCT00704028 · American Regent, Inc.
2008-06 – 2011-03 · Anemia
What this study did
NCT00704353 · American Regent, Inc.
2008-06 – 2011-03 · Anemia
What this study did
NCT00821717 · Vifor Pharma
2008-12 – 2011-01 · Chronic Heart Failure, Iron Deficiency, Iron Deficiency Anemia, Anaemia
What this study did
NCT00810030 · Vifor Pharma
2008-10 – 2010-04 · Inflammatory Bowel Disease, Anemia, Iron Deficiency, Iron-Deficiency Anemia, Crohn's Disease, Ulcerative Colitis
What this study did
NCT00520780 · Vifor Pharma
2007-04 – 2009-09 · Chronic Heart Failure, Iron Deficiency, Iron Deficiency Anemia, Anaemia
What this study did
NCT00548860 · American Regent, Inc.
2007-10 – 2009-07 · Anemia
What this study did
NCT00740246 · American Regent, Inc.
2005-07 – 2006-05 · Anemia
What this study did
Other / comorbidity
NCT05744219 · Jon Unosson
2024-09-04 – 2028-03-30 · Surgery, Liver Metastases, Liver Cancer, Pancreas Cancer, Aortic Aneurysm
What this study did
NCT04625530 · University Hospital, Basel, Switzerland
2021-08-01 – 2026-12-31 · Gynaecological Carcinoma
What this study did
NCT05226169 · Asan Medical Center
2022-04-29 – 2026-11-30 · Advanced Gastric Carcinoma
What this study did
NCT03769441 · University Medical Center Groningen
2019-08-02 – 2024-08-19 · Iron-deficiency, Transplant-Related Disorder
What this study did
NCT04187716 · Samsung Medical Center
2020-02-01 – 2020-12-01 · Cancer Anaemia
What this study did
NCT01692418 · University College, London
2014-01 – 2019-05 · Anaemia
What this study did
NCT01513369 · GWT-TUD GmbH
2012-08 – 2019-04 · Type 2 Diabetes Mellitus, Iron Deficiency
What this study did
NCT02453334 · American Regent, Inc.
2015-05-23 – 2018-01-04 · Cancer and Chemotherapy Related Anemia
What this study did
NCT02397057 · American Regent, Inc.
2015-01 – 2018-01 · Restless Legs Syndrome (RLS)
What this study did
NCT01690585 · University Hospital, Rouen
2013-01 – 2017-07 · Gastrointestinal Hemorrhage, Anemia
What this study did
NCT02125344 · GBG Forschungs GmbH
2014-12 – 2017-01-30 · Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer
What this study did
NCT01787526 · Medical University of Graz
2014-06 – 2016-08 · Iron Deficiency
What this study did
NCT01725789 · National Cancer Center, Korea
2012-11 – 2016-04 · Anemia
What this study did
NCT01154491 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2010-06 – 2013-05 · Hip Fractures
What this study did
NCT00810004 · Vifor Pharma
2009-02 – 2010-10 · Iron Deficiency, Inflammatory Bowel Disease
What this study did
NCT00354484 · American Regent, Inc.
2006-05 – 2007-01 · Postpartum Anemia
What this study did
NCT00395993 · American Regent, Inc.
2005-05 – 2006-06 · Anemia
What this study did
NCT00396292 · American Regent, Inc.
2005-02 – 2006-02 · Anemia
What this study did
Phase 2/3 (3)
Iron Deficiency Anemia
NCT07648628 · ESI-PGIMSR, Basaidarapur
2024-03-01 – 2025-08-16 · Anemia, Anemia, Postpartum, Iron Deficiency Anemia of Pregnancy, Iron Deficiency Anemia Treatment, FCM
What this study did
Other / comorbidity
NCT07217873 · Columbia University
2025-11-21 – 2027-10-31 · Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent, Scoliosis Neuromuscular
What this study did
NCT00929409 · Norwegian University of Science and Technology
2009-06 – 2010-07 · Anemia, Iron-Deficiency, Puerperal Disorders, Depression, Postpartum
What this study did
Phase 2 (19)
Heart Failure
NCT03218384 · NYU Langone Health
2017-09-07 – 2022-04-04 · Iron-deficiency
What this study did
NCT03079518 · RWTH Aachen University
2017-03-10 – 2017-10-25 · Heart Failure, Systolic, Iron Deficiency
What this study did
Iron Deficiency Anemia
NCT04968379 · American Regent, Inc.
2022-07-21 – 2024-12-12 · Iron Deficiency, Anaemia
What this study did
NCT02826681 · American Regent, Inc.
2017-07-10 – 2022-07-01 · Restless Legs Syndrome (RLS)
What this study did
NCT02469480 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2015-03 – 2020-08 · Metastatic Colorectal Cancer
What this study did
NCT02949947 · M.D. Anderson Cancer Center
2017-12-18 – 2019-03-06 · Malignant Neoplasms of Mesothelial and Soft Tissue, Gastrointestinal Stromal Tumor With Neurogenic Differentiation
What this study did
NCT02410213 · American Regent, Inc.
2015-02-19 – 2017-06-01 · Iron Deficiency Anemia (IDA)
What this study did
NCT01307007 · American Regent, Inc.
2010-09 – 2013-08 · Iron Deficiency Anemia
What this study did
NCT01290315 · American Regent, Inc.
2009-08 – 2013-08 · Iron Deficiency Anemia
What this study did
NCT00882414 · Vifor Pharma
2006-12 – 2010-01 · Thrombocytosis, Iron-Deficiency Anemia
What this study did
Other / comorbidity
NCT07822607 · University Hospital, Montpellier
2026-10 – 2030-10 · Restless Legs Syndrome (RLS)
What this study did
NCT02628860 · National Cancer Center, Korea
2014-01 – 2020-04-27 · Pancreatic Cancer, Anemia
What this study did
NCT03050424 · Royal Brompton & Harefield NHS Foundation Trust
2017-04-01 – 2019-01-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01447628 · Imperial College London
2011-03-29 – 2017-12-22 · Pulmonary Arterial Hypertension, Iron Deficiency
What this study did
NCT02599012 · Samsung Medical Center
2015-09-12 – 2017-12 · Cancer, Anemia
What this study did
NCT02517151 · Istituto Clinico Humanitas
2014-10 – 2016-12 · Chronic Fatigue, Inflammatory Bowel Disease
What this study did
NCT02409459 · American Regent, Inc.
2015-03 – 2016-03 · Iron Deficiency, Fibromyalgia
What this study did
NCT00685815 · American Regent, Inc.
2006-11 – 2012-12 · Restless Legs
What this study did
NCT01382901 · American Regent, Inc.
2006-03 – 2007-07 · Restless Legs Syndrome (RLS)
What this study did
Phase 1 (6)
Heart Failure
NCT02737995 · NYU Langone Health
2015-05 – 2016-01 · Chronic Heart Failure
What this study did
Iron Deficiency Anemia
NCT03399084 · Sandoz
2017-11-29 – 2019-01-15 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT07606105 · Sichuan Huiyu Pharmaceutical Co., Ltd
2026-05-19 – 2027-01-26 · Healthy Adult
What this study did
NCT06895993 · Sichuan Huiyu Pharmaceutical Co., Ltd
2025-04-07 – 2025-05-08 · Healthy Adult
What this study did
NCT06080555 · Sichuan Huiyu Pharmaceutical Co., Ltd
2023-10-09 – 2024-03-22 · Iron Deficiency, Anaemia
What this study did
NCT02009943 · Denver Health and Hospital Authority
2017-02 – 2017-09 · ICU Anemia, Functional Iron Deficiency
What this study did
Phase 4 (66)
Chronic Kidney Disease
NCT07414199 · Children's Hospital of Orange County
2026-01-31 – 2026-12-31 · Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease, Iron Deficiency Anaemia Due to Dietary Causes, Iron Deficiency Anemia Treatment, Iron Deficiency Anemia Secondary to IBD or Gastric Bypass, Iron Deficiency Anemias
What this study did
NCT03388385 · Carol Davila University of Medicine and Pharmacy
2017-09-20 – 2022-12-20 · Renal Anemia, Iron Toxicity, Oxidative Stress, Endothelial Dysfunction
What this study did
NCT04862715 · King's College Hospital NHS Trust
2019-04-26 – 2022-02-21 · CKD Stage 3, CKD Stage 4, Iron-deficiency
What this study did
NCT02198495 · Medical University of Vienna
2014-09 – 2019-05 · Anemia of Chronic Kidney Disease
What this study did
NCT02232906 · Hospital Aleman
2011-03 – 2013-09 · Iron Deficiency, Anaemia
What this study did
Heart Failure
NCT05793996 · Tomsk National Research Medical Center of the Russian Academy of Sciences
2023-04-28 – 2026-12 · Chronic Heart Failure, Iron Deficiency, Latent
What this study did
NCT03074591 · Charite University, Berlin, Germany
2017-08-01 – 2024-04-10 · Iron-deficiency, Heart Failure
What this study did
NCT05477498 · Cantonal Hospital, Baselland
2021-12-01 – 2022-12-31 · Heart Failure With Normal Ejection Fraction, Iron-deficiency
What this study did
NCT03380520 · Hasselt University
2017-10-01 – 2021-08-04 · Heart Failure
What this study did
NCT03871699 · Hospital Moinhos de Vento
2019-08-30 – 2021-02-28 · Cardiac Failure, Systolic Heart Failure, Heart Failure, Systolic
What this study did
NCT02937454 · Vifor (International) Inc.
2017-04-03 – 2020-07-21 · Iron Deficiency, Heart Failure
What this study did
NCT01978028 · University of Zurich
2013-10 – 2017-12-31 · Heart Failure
What this study did
NCT01922479 · National University Hospital, Singapore
2013-09 – 2015-12 · Heart Failure, Anemia, Iron Deficiency
What this study did
NCT01453608 · Vifor Pharma
2011-10 – 2015-01 · Iron Deficiency, Chronic Heart Failure
What this study did
Iron Deficiency Anemia
NCT07772453 · Zhaojian Niu,MD
2026-08 – 2028-03 · Gastric Cancer (GC), Iron Deficiency Anemia (IDA), Post-Operative Anemia, Radical Gastrectomy
What this study did
NCT06061393 · Western Galilee Hospital-Nahariya
2023-11-02 – 2027-12 · Anemia, Iron Deficiency, Pregnancy Anemia
What this study did
NCT05708170 · Liverpool Hope University
2023-01 – 2027-01 · Iron Deficiency Anemia
What this study did
NCT04168346 · Helsinki University Central Hospital
2019-11 – 2026-11 · Gastric Cancer, Anemia, Surgery, Iron Deficiency Anemia, Surgery--Complications
What this study did
NCT07880314 · Pakistan Air Force (PAF) Hospital Islamabad
2026-04-20 – 2026-09-20 · Postpartum Fatigue, Iron Deficiency Anemia
What this study did
NCT07053475 · Syed Hamza Mufarrih
2025-04-02 – 2026-03-31 · Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
What this study did
NCT06911034 · CMH Multan Institute of Medical Sciences
2024-02-01 – 2024-09-30 · Iron Deficiency Anemia (IDA), Pregnancy
What this study did
NCT05358509 · Thomas Jefferson University
2021-03-15 – 2024-01-21 · Iron Deficiency Anemia, Infant, Low Birth Weight, Anemia of Pregnancy
What this study did
NCT05098249 · Donat R. Spahn
2021-11-11 – 2023-05-23 · Anemia, Iron-deficiency, Hypophosphatemia
What this study did
NCT04616092 · Seoul National University Hospital
2020-11 – 2023-04 · Cerebral Aneurysm Unruptured, Iron Deficiency Anemia, Surgery
What this study did
NCT04627181 · Christian Medical College, Vellore, India
2020-11-18 – 2021-03 · Iron Deficiency Anemia, B12 Deficiency Anemia
What this study did
NCT02086968 · American Regent, Inc.
2014-01-01 – 2017-10 · Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
What this study did
NCT01950247 · American Regent, Inc.
2013-08-15 – 2015-06 · Iron Deficiency Anemia (IDA)
What this study did
NCT00706667 · University of Zurich
2008-05 – 2012-12 · Iron Deficiency Anemia
What this study did
NCT01245777 · University of Zurich
2009-10 – 2012-12 · Restless Leg Syndrome, Iron Deficiency Anemia
What this study did
NCT01100879 · Vifor Pharma
2010-03 – 2011-10 · Iron-Deficiency Anemia
What this study did
Other / comorbidity
NCT06833788 · Assistance Publique - Hôpitaux de Paris
2025-10-22 – 2028-10-30 · Postpartum Depression (PPD)
What this study did
NCT07359599 · Ziekenhuis Oost-Limburg
2026-01-27 – 2028-10 · Pulmonary Hypertension, Iron Deficiency
What this study did
NCT07370688 · Erasmus Medical Center
2024-08-12 – 2028-07 · Aortic Valve Stenosis, Iron Deficiency, TAVI(Transcatheter Aortic Valve Implantation), Cardiovascular Diseases
What this study did
NCT07476859 · Fundación para la Investigación del Hospital Clínico de Valencia
2026-03-05 – 2028-05 · Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)
What this study did
NCT05759078 · Wroclaw Medical University
2022-09-22 – 2026-12-31 · Myocardial Infarction, Acute
What this study did
NCT04083755 · Biobizkaia Health Research Institute
2019-08-15 – 2025-12-31 · Anemia, Peripheral Arterial Occlusive Disease
What this study did
NCT06686693 · United States Army Research Institute of Environmental Medicine
2022-04-15 – 2025-09-30 · Hypoxia
What this study did
NCT04786769 · Hospital de Santa Cruz, Portugal
2022-01 – 2025-06 · Aortic Stenosis, Iron-deficiency
What this study did
NCT06080893 · Istanbul University
2023-10-10 – 2025-03-24 · Hip Fractures, Anemia, Complication,Postoperative
What this study did
NCT03680456 · Kepler University Hospital
2020-03-06 – 2025-01-31 · Blood Loss Anemia
What this study did
NCT05429749 · Seoul National University Bundang Hospital
2020-07-30 – 2024-12-31 · Hip Fractures
What this study did
NCT02632760 · Bayside Health
2016-07-15 – 2024-11-27 · Anaemia
What this study did
NCT05505006 · Azienda Ospedaliera Universitaria Integrata Verona
2021-03-02 – 2024-08-13 · Anemia, Tumor
What this study did
NCT03574311 · Turku University Hospital
2018-10-02 – 2023-12 · Coronary Artery Disease, Postoperative Complications, Aortic Valve Stenosis, Mitral Valve Disease, Aortic Aneurysm, Thoracic
What this study did
NCT05114278 · Assistance Publique - Hôpitaux de Paris
2022-07-08 – 2023-07-11 · Celiac Disease
What this study did
NCT04510870 · Dextra Fertility Clinic
2020-08-17 – 2022-02-28 · Iron Deficiency, Infertility
What this study did
NCT04035902 · Konkuk University Medical Center
2021-03 – 2021-12 · Osteoarthritis, Hip
What this study did
NCT03632525 · University of Oxford
2019-02-22 – 2021-10-26 · Cystic Fibrosis, Iron-deficiency
What this study did
NCT03759964 · St Joseph University, Beirut, Lebanon
2018-12-15 – 2021-01-02 · Anemia, Iron Deficiency
What this study did
Early phase / not applicable (20)
Chronic Kidney Disease
NCT06994065 · Sindh Institute of Urology and Transplantation
2025-04-01 – 2025-11-30 · Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
What this study did
Iron Deficiency Anemia
NCT07721519 · Hawler Medical University
2026-09-01 – 2028-12-01 · Iron Deficiency Anemia in Pregnancy
What this study did
NCT04915820 · Jomo Kenyatta University of Agriculture and Technology
2021-05-29 – 2021-09-09 · Iron Deficiency Anemia, Vaccine Response Impaired, COVID-19 Vaccine, Iron Deficiency Anemia Treatment
What this study did
NCT04912661 · Swiss Federal Institute of Technology
2021-05-29 – 2021-09-09 · Iron Deficiency Anemia, Vaccine Preventable Disease, Vaccine Response Impaired, Iron Deficiency Anemia Treatment
What this study did
NCT03625661 · Institut Cancerologie de l'Ouest
2014-02-02 – 2017-06-12 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT07057973 · Xuanwu Hospital, Beijing
2025-07-01 – 2026-07-01 · Ferric Carboxymaltose
What this study did
NCT04653181 · Helsinki University Central Hospital
2020-10-01 – 2025-12-31 · Colon Cancer
What this study did
NCT05669872 · Asan Medical Center
2023-02 – 2025-12 · Gynecologic Cancer
What this study did
NCT06437080 · Akram Medical Complex
2022-10-10 – 2025-10-16 · Hypoferritenemia Without Anemia (HWA), Iron Deficiency Without Anemia)
What this study did
NCT05309499 · Kazan State Medical University
2021-12-05 – 2025-09-15 · Myocardial Infarction, Iron-deficiency
What this study did
NCT07340450 · Shahida Islam Medical Complex
2025-02-18 – 2025-08-18 · Postpartum Anaemia
What this study did
NCT07115121 · Muhammad Aamir Latif
2025-02-02 – 2025-07-31 · Anemia
What this study did
NCT04141631 · University Hospital, Montpellier
2020-01-13 – 2022-06-15 · Cardiac Surgery, Transfusion, Perioperative Anemia
What this study did
NCT02979132 · Prof. Michael B. Zimmermann
2017-09-01 – 2019-03-31 · Iron Absorption
What this study did
NCT02800746 · Konkuk University Medical Center
2018-06 – 2018-12 · Prognathic Surgery
What this study did
NCT04246021 · King Hussein Cancer Center
2016-06-15 – 2017-12-31 · Anemia, Cancer
What this study did
NCT03707249 · Royal Centre for Defence Medicine
2016-01-19 – 2017-12-07 · Iron-deficiency, Ventricular Function, Pulmonary Vascular Resistance Abnormality, Altitude Hypoxia
What this study did
NCT02496377 · University Hospital, Montpellier
2014-08-29 – 2016-10-16 · Allogenic Transfusion, Perioperative Anaemia, Knee Arthroplasty, Hip Arthroplasty
What this study did
NCT02308449 · University of Oxford
2014-10 – 2016-01 · Iron Deficiency
What this study did
NCT01847352 · University of Oxford
2013-02 – 2014-04 · Lung Hypoxia, Pulmonary Arterial Hypertension, Iron Deficiency
What this study did
Used as active comparator (11)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Iron Deficiency Anemia
NCT07687784 · AFT Pharmaceuticals, Ltd.
2026-12 – 2028-07 · Iron Deficiency Anemia (IDA)
What this study did
NCT03817957 · Prof. Dr. Frank Behrens
2018-09-18 – 2024-10-21 · Iron Deficiency Anemia
What this study did
NCT04587141 · Fondazione IRCCS Policlinico San Matteo di Pavia
2020-01-01 – 2023-06-30 · Iron Deficiency Anemia, Inflammatory Bowel Diseases
What this study did
NCT04087993 · Dr. Frank Behrens
2020-05-15 – 2020-12-31 · Iron Deficiency Anemia
What this study did
NCT03238911 · Pharmacosmos A/S
2017-10-24 – 2018-06-19 · Iron Deficiency Anaemia, Iron Deficiency Anemia
What this study did
NCT03237065 · Pharmacosmos A/S
2017-10-30 – 2018-05-29 · Iron Deficiency Anaemia, Iron Deficiency Anemia
What this study did
NCT02694978 · AMAG Pharmaceuticals, Inc.
2016-02-29 – 2017-07-17 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT02680756 · Shield Therapeutics
2016-01 – 2019-01 · Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
What this study did
Phase 4 (3)
Heart Failure
NCT05702970 · University of Padova
2024-01-15 – 2025-10-31 · Heart Failure, Iron-deficiency, Heart Failure, Systolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Vitamin D Deficiency
What this study did
Other / comorbidity
NCT02905539 · Universität des Saarlandes
2016-07 – 2020-06 · Anemia, Iron-Deficiency
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Iron Deficiency Anemia
NCT04343170 · Tanta University
2023-09-01 – 2024-10-01 · Ultra-short-term, Iron Deficiency Anemia, Scoliosis Idiopathic
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Kidney Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ferric Carboxymaltose (Injectafer / Ferinject): this drugApprovedIron Complex (iv)Iron repletionPartial signal
NCT00317239: Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL (anytime during the study): Ferric Carboxymaltose (FCM) 87/144 vs Ferrous Sulfate Tablets 35/101
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Reliable signal
NCT03436693: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029)
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT03036150: Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001
Difelikefalin (Korsuva)ApprovedPeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT03636269: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 54% (95% CI 43.9 to 63.9) vs Placebo 42.2% (95% CI 32.5 to 52.5)
NCT03422653: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 51% (95% CI 42.9 to 58.9) vs Placebo 27.6% (95% CI 20.2 to 36.6)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03594110: Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met.
NCT05373680: Adjusted mean difference in eGFR decline vs standard-of-care control: metformin +8.91 ± 1.92 (p<0.001); empagliflozin +5.1 ± 1.89 (p=0.03) — both halted CKD progression vs control.
Etelcalcetide (Parsabiv)ApprovedPeptideCalcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cellsPartial signal
NCT01785849: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 74% vs Placebo 8.3%
NCT01788046: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 75.3% vs Placebo 9.6%
Extended-Release Calcifediol (Rayaldee)ApprovedSmall moleculeVitamin D receptor (VDR), via conversion to calcitriolPartial signal
NCT01704079: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline (Approximately 6 months): CTAP101 30 μg Capsules 49/144 (34.0%) vs Sugar Pill to CTAP101 30 μg 5/72 (6.9%)
NCT01651000: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values (Approximately 6 months): CTAP101 30 μg Capsules 46/141 (32.6%) vs Sugar Pill to CTAP101 30 μg Capsule 6/72 (8.3%)
Ferric Derisomaltose (Monoferric / Monofer)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT02940860: Change in Hemoglobin (Hb) From Baseline to Week 8 (Baseline to week 8): Iron Isomaltoside/Ferric Derisomaltose 1.22 g/dL (95% CI 1.14 to 1.31) vs Iron Sucrose 1.14 g/dL (95% CI 1.03 to 1.26)
NCT01102413: Change in Hemoglobin (Hb) Concentration From Baseline to Week 4. (Baseline, 4 weeks): Monofer 0.57 g/dL (range -3.1 to 4) vs Iron Sulphate 0.35 g/dL (range -3.7 to 3.9)
Ferric Pyrophosphate Citrate (Triferic)
ApprovedUS marketing discontinued
Small moleculeIron-replacement therapy delivered via dialysateWeak signalNo reviewed efficacy summary in this indication
Ferumoxytol (Feraheme)ApprovedNanoparticleIV iron replacement therapyPartial signal
NCT00255424: Primary endpoint (hemoglobin change at day 35): ferumoxytol +0.82 ± 1.24 g/dl vs oral iron +0.16 ± 1.02 g/dl, P<0.0001, in favor of ferumoxytol. CT.gov's own citation list ties this Spinowitz 2008 publication specifically to NCT00255424 (not its twin trial NCT00255437).
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT05047263: Total eGFR slope, baseline to month 32 (FIND-CKD): -3.3 mL/min/1.73m2/year finerenone vs -4.0 mL/min/1.73m2/year placebo; between-group difference 0.7 mL/min/1.73m2/year (95% CI 0.3-1.1; p<0.001)
NCT02540993: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death (From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months): Finerenone 504/2833 vs Placebo 600/2841
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
Sucroferric Oxyhydroxide (Velphoro)ApprovedSmall moleculeDietary phosphatePartial signal
NCT03644264: Change in serum phosphorus from baseline to week 12: -0.71 (0.60) mmol/L with sucroferric oxyhydroxide vs -0.63 (0.52) mmol/L with sevelamer; difference in least squares means 0.08 mmol/L (95% CI -0.02, 0.18), meeting the pre-specified non-inferiority margin of -0.34 mmol/L
NCT01464190: Change From Baseline and Levels at Each Time Point for Serum Phosphorus (Every 4 weeks from baseline to Week 28): PA21 — Change from Baseline to Week 4 (n = 346, 236): -0.2 mg/dL (Standard Deviation 1.33); Change from Baseline to Week 8 (n = 325, 238): -0.2 mg/dL (Standard Deviation 1.38); Change from Baseline to Week 12 (n = 322, 242): 0 mg/dL (Standard Deviation 1.43); Change from Baseline to Week 16 (n = 313, 228): 0 mg/dL (Standard Deviation 1.57); Change from Baseline to Week 20 (n = 300, 221): 0 mg/dL (Standard Deviation 1.46); Change from Baseline to Week 24 (n = 286, 208): 0.1 mg/dL (Standard Deviation 1.53); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.52); Change from Baseline to Endpoint (n = 384, 260): 0.1 mg/dL (Standard Deviation 1.62) vs Sevelamer Carbonate — Change from Baseline to Week 4 (n = 346, 236): -0.1 mg/dL (Standard Deviation 1.47); Change from Baseline to Week 8 (n = 325, 238): 0.1 mg/dL (Standard Deviation 1.56); Change from Baseline to Week 12 (n = 322, 242): 0.2 mg/dL (Standard Deviation 1.55); Change from Baseline to Week 16 (n = 313, 228): 0.2 mg/dL (Standard Deviation 1.75); Change from Baseline to Week 20 (n = 300, 221): 0.1 mg/dL (Standard Deviation 1.44); Change from Baseline to Week 24 (n = 286, 208): 0.2 mg/dL (Standard Deviation 1.78); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.76); Change from Baseline to Endpoint (n = 384, 260): 0.3 mg/dL (Standard Deviation 1.79)
Taurolidine / Heparin (Defencath / Neutrolin)ApprovedSmall moleculeAntimicrobial/antithrombotic catheter lock solutionReliable signal
NCT02651428: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD): Final Analysis (The event time was the number of days from randomization until the occurrence of a CAC-Adjudicated CRBSI or until the subject was censored. The mean participant duration of exposure to study drug was 174 days (range 4-884 days).): Neutrolin Arm 9/397 vs Heparin Arm 32/398
Tenapanor (Xphozah)ApprovedSmall moleculeNHE3 (sodium/hydrogen exchanger isoform 3)Partial signal
NCT03427125: Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population (12 weeks (randomized withdrawal period)): Tenapanor 10 mg, 20 mg, 30 mg BID 0.43 mg/dL (Standard Deviation 0.199) | Placebo 1.8 mg/dL (Standard Deviation 0.196)
NCT02675998: Primary 4-week randomized-withdrawal serum phosphate change: pooled tenapanor 1.4 mg/dL vs placebo 0.6 mg/dL (p=0.01).
Vadadustat (Vafseo)ApprovedSmall moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT02680574: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 0.41 Grams per deciliter (g/dL) (Standard Error 0.036) vs Darbepoetin Alfa 0.42 Grams per deciliter (g/dL) (Standard Error 0.037)
NCT02648347: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 1.43 g/dL (Standard Error 0.046) vs Darbepoetin Alfa 1.38 g/dL (Standard Error 0.047)
AND017Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signalNo reviewed efficacy summary in this indication
Anrikefon (HSK21542)Phase 3PeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT05135390: Proportion with ≥4-point WI-NRS improvement at week 12: anrikefon 37% vs placebo 15% (P<0.001)
AP301 (fiber-Iron Phosphate Binder)Phase 3Small moleculeIron-based intestinal phosphate binderPartial signal
NCT07030595: Primary 1, serum phosphate change baseline to week 12, AP301 vs sevelamer carbonate (non-inferiority, margin 0.19 mmol/L): LSM difference -0.02 mmol/L (95% CI -0.10 to 0.06), upper bound below margin, met. Primary 2, serum phosphate change week 24 to week 27, AP301 maintenance dose vs low dose: LSM difference -0.58 mmol/L (95% CI -0.69 to -0.47; P<0.001), equivalent to -1.8 mg/dL, met.
ApecotrepPhase 3Small moleculeTRPC6 (transient receptor potential cation channel subfamily C member 6)Partial signal
NCT05213624: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 (At baseline and Week 12.): BI 764198 20 mg 48.9 Predicted percentage of patients (95% CI 29.2 to 68.6) | BI 764198 40 mg 16 Predicted percentage of patients (95% CI -1.5 to 33.5) | BI 764198 80 mg 38.5 Predicted percentage of patients (95% CI 12.2 to 64.8) vs Placebo 11.4 Predicted percentage of patients (95% CI -2.3 to 25.2)
NCT04176536: Single 40mg dose, matched-pair renal-impairment vs normal-renal-function design (NCT04176536): AUC increased 48% (moderate) / 78% (severe) renal impairment vs healthy controls; Cmax increased 14% / 12%; terminal half-life 12.7-17.4h independent of dose and renal function.
AST-120 (Kremezin)Phase 3Small moleculeOral spherical carbon adsorbentPartial signal
NCT00500682: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 1.03 (95% CI 0.84 to 1.27), P=0.78; events AST-120 178/500 vs placebo 177/502. missed
NCT00501046: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 0.91 (95% CI 0.74 to 1.12), P=0.37; events AST-120 172/500 vs placebo 183/497. missed
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signal
NCT04595370: Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): AZD9977 15 mg + Dapagliflozin 10 mg -56.391% (95% CI -71.528--33.207) vs AZD9977 50 mg + Dapagliflozin 10 mg -42.085% (95% CI -64.174--6.376) vs AZD9977 150 mg + Dapagliflozin 10 mg -58.047% (95% CI -73.560--33.430) vs AZD9977 150 mg -45.01% (95% CI NA-NA) vs Dapagliflozin 10 mg -34.318% (95% CI -58.204-3.220) vs Placebo 230.32% (95% CI NA-NA); p=0.3645 (AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg) missed
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
BHV-1400Phase 3Biologic (subtype unspecified)Gd-IgA1 (galactose-deficient IgA1)not yet gradedNo reviewed efficacy summary in this indication
Bixalomer (Kiklin)Phase 3Small moleculePhosphate binderWeak signal
NCT01742585: Change in serum phosphorus, baseline to end of treatment (12 weeks): bixalomer -0.78 mg/dL (95% CI -0.98, -0.57) vs placebo 0.20 mg/dL (95% CI -0.00, 0.41); mean difference -0.98 mg/dL (95% CI -1.27, -0.69), P < 0.001.
NCT01742611: Mean serum phosphorus: 5.15 mg/dL at baseline, decreasing to 4.67 mg/dL at Week 12, reaching 4.58 mg/dL at Week 48 of open-label bixalomer treatment
Colestilan (Cholebine / BindRen)Phase 3Small moleculePhosphate binderPartial signal
NCT00542815: Primary outcome, change in serum phosphorus from baseline to week 52 in an open-label long-term safety study (no comparator test): -1.23 mg/dL (colestilan from E07/E08), -1.47 mg/dL (colestilan from E07) and -2.26 mg/dL (sevelamer from E07) (CT.gov posted results).
NCT00416520: Serum phosphorus at week 16 (end of the 4-week placebo-controlled withdrawal): 0.43 mmol/L (1.32 mg/dL) lower with colestilan than with placebo (P<0.001) (Locatelli et al., Nephrol Dial Transplant 2014).
Desidustat (Oxemia)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT04215120: Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382)
NCT04012957: Change in hemoglobin baseline to week 16-24: desidustat +1.95 g/dL vs darbepoetin +1.83 g/dL (difference 0.11 g/dL, 95% CI -0.12 to 0.34), met prespecified noninferiority margin of -0.75 g/dL; hemoglobin responders 77.78% desidustat vs 68.48% darbepoetin (p=0.0181)
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
EnarodustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT06016036: Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001
NCT04027517: 평가기간 중 투여군간 차이 [95% 신뢰구간] -0.19 [-0.46, 0.08] (이 약 투여군 N=57 평가기간 중 Hb 농도 평균 10.65 g/dL, 다베포에틴 알파 투여군 N=67 10.83 g/dL; 베이스라인 10.73 vs 10.68 g/dL; 비열등성 마진 -1.0 g/dL)
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
HRS-1780Phase 3Small moleculeMineralocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Imlifidase (Idefirix)Phase 3Protein / enzyme therapeuticImmunoglobulin G (IgG), all four human subclassesWeak signal
NCT02790437: Crossmatch conversion (positive to negative) within 24 hours of IdeS dosing: 17 of 19 patients converted; 2 of 19 did not.
Iptacopan (Fabhalta)Phase 3Small moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
NCT03373461: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 (Baseline and Day 90): LNP023 10 mg BID 0.85 Ratio to baseline (95% CI 0.77-0.93) vs LNP023 50 mg BID 0.80 Ratio to baseline (95% CI 0.73-0.87) vs LNP023 100 mg BID - Part 2 0.76 Ratio to baseline (95% CI 0.70-0.81) vs LNP023 200 mg BID 0.69 Ratio to baseline (95% CI 0.61-0.77) vs Placebo 0.88 Ratio to baseline (95% CI 0.80-1.00); p=0.038 (LNP023 10 mg BID vs LNP023 50 mg BID vs LNP023 100 mg BID - Part 2 vs LNP023 200 mg BID vs Placebo)
JR-131Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT02912494: Change in Hb level from baseline to end of treatment (24 weeks): JR-131 −0.42 ± 0.73 g/dL vs darbepoetin alfa −0.43 ± 0.77 g/dL; between-group difference 0.01 g/dL (95% CI −0.19 to 0.20), within the prespecified equivalence margin of −0.5 to 0.5 g/dL
Loncipoetin Alfa (NuPIAO)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT05211167: Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given.
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
MolidustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT03543657: Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established
NCT03350347: Mean Hb during the week 30-36 evaluation period: 11.67 g/dL molidustat vs 11.53 g/dL darbepoetin; LS mean difference 0.13 g/dL (95% CI -0.15 to 0.40), inside the 1.0 g/dL noninferiority margin.
MT1013Phase 3PeptideCaSR; OGPPartial signalNo reviewed efficacy summary in this indication
NNG-DEPO (Stimus)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signalNo reviewed efficacy summary in this indication
Patiromer (Veltassa)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT01810939: Change in Serum Potassium From Part A Baseline to Part A Week 4 (Part A Baseline to Part A Week 4): Part A Patiromer -1.01 mEq/L (Standard Error 0.031)
Pegmolesatide (HS-20039)Phase 3PeptideErythropoietin receptor (EPO-R)Reliable signal
NCT03903809: Mean Hb change from baseline: pegmolesatide +19.2 g/L vs epoetin alfa +15.4 g/L; between-group difference 3.8 g/L (95% CI 0.7-6.9), noninferiority margin -10 g/L
NCT03902691: Mean change in hemoglobin (baseline to evaluation period): +0.07 g/dL pegmolesatide vs -0.22 g/dL epoetin alfa; between-group difference 0.29 g/dL (95% CI 0.11-0.47), non-inferiority verified
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
Rilparencel (Neo-Kidney Augment / REACT)Phase 3Cell therapySelected renal cells (autologous, paracrine)Weak signal
NCT05018416: Primary endpoint (difference in annual eGFR slope, pre- vs post-treatment): Group 1 (n=24) -5.8 to -1.3 mL/min/1.73m2, difference 4.6 per year, 78% improvement, P < .001; Group 2 (n=25) -3.4 to -1.7 mL/min/1.73m2, difference 1.7 per year, 50% improvement, P = .085
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Reliable signal
NCT01750190: Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001).
NCT01887600: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response (Baseline to week 24): Roxadustat 79.2% (95% CI 74.8 to 83.1) vs Placebo 9.9% (95% CI 6.1 to 14.8)
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SC0062Phase 3Small moleculeEndothelin receptor type A (ETA)not yet gradedNo reviewed efficacy summary in this indication
SHR6508Phase 3Small moleculeCalcium-sensing receptor (CaSR)Weak signalNo reviewed efficacy summary in this indication
Sodium Zirconium Cyclosilicate (Lokelma)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT05056727: Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69)): Maintenance Phase: SZC -5.2975 mL/min/(1.73 m2)/yr (95% CI -6.6854 to -3.9097) vs Maintenance Phase: Placebo -4.5622 mL/min/(1.73 m2)/yr (95% CI -5.9969 to -3.1275) missed
Somatropin (Jintropin)Phase 3Biologic (subtype unspecified)Growth hormone receptorPartial signal
NCT03535415: HT-SDS change at week 52: +0.75 (rhGH-treated) vs +0.17 (untreated control), reported as statistically significant; enrollment (68) and design match NCT03535415 exactly, and the paper is indexed against this NCT.
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)Partial signal
NCT03242018: Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo (Baseline to Week 26): Sotagliflozin 400 mg -0.4 percentage of HbA1c (Standard Error 0.131) vs Placebo -0.11 percentage of HbA1c (Standard Error 0.151) missed
NCT03242252: Change From Baseline in HbA1c at Week 26 (Baseline to Week 26): Sotagliflozin 200 mg -0.32 percentage of HbA1c (Standard Error 0.06) | Sotagliflozin 400 mg -0.46 percentage of HbA1c (Standard Error 0.06) vs Placebo -0.22 percentage of HbA1c (Standard Error 0.061)
Upacicalcet (UPASITA)Phase 3Small moleculeCalcium-sensing receptor (CaSR)Partial signal
NCT05836220: PATH-2, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 43.5% versus 17.4%, for a difference in proportions of 26.1% (95% confidence interval, 17.4 to 34.8, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
NCT05832931: PATH-1, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 42.1% versus 16.8%, for a difference in proportions of 25.3% (95% confidence interval, 16.2 to 34.5, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)Partial signal
NCT06531824: Discontinued by Boehringer Ingelheim on an independent Data Monitoring Committee recommendation: accumulating data did not support a meaningful expectation of benefit on the primary composite endpoint vs empagliflozin alone (September 2026). missed
NCT05182840: Change in log UACR at week 14 (all patients): 10 mg -0.553 vs placebo -0.066 (difference -0.486, 95% CI -0.660 to -0.313, p<0.0001); 20 mg -0.487 (difference -0.421, 95% CI -0.596 to -0.246, p<0.0001); 3 mg -0.235 (difference -0.168, 95% CI -0.337 to -0.000, p=0.0499). Adjusted median percent change: 10 mg -42.5% vs placebo -6.4%.
Zibotentan + DapagliflozinPhase 3Small moleculeEndothelin A receptor, SGLT2not yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
InaxaplinPhase 2/3Small moleculeAPOL1 (Apolipoprotein L1)Weak signal
NCT06794996: Single-group Phase 2b AMPLIFIED: UACR -42.7% (cohort 1) and -17.3% (AMKD with type 2 diabetes) from baseline at Week 13 (Vertex, 2026-09-22).
NCT04340362: The primary outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13 in participants with at least 80% adherence to inaxaplin therapy. Sixteen participants were enrolled; among the 13 who were treated and met the adherence threshold, the mean change from baseline at week 13 was -47.6% (95% confidence interval, -60.0 to -31.3).
KT-301Phase 2/3Microbiome therapeuticProbiotic live biotherapeuticnot yet gradedNo reviewed efficacy summary in this indication
AB002Phase 2Protein / enzyme therapeuticProtein CPartial signal
NCT03963895: Primary outcomes: 40 registered safety and tolerability counts (treatment-related adverse events, access-site bleeding, ECG, anti-thrombin antibodies, vital signs and laboratory changes); safety outcome, no formal efficacy test. Treatment-related TEAEs: 0 in each AB002 dose group and 0 with placebo (CT.gov posted results).
ALN-ANG3Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
Avacopan (Tavneos)Phase 2Small moleculeComplement C5a receptor 1 (C5aR1/CD88)Weak signalFeatured results are pharmacokinetic only in this race
CagrilintidePhase 2PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signalNo reviewed efficacy summary in this indication
CU01-1001Phase 2Small moleculeNrf2 / TGF-betaPartial signal
NCT05718375: Change in UACR at Week 24 vs placebo: low-dose -21.45% (p=0.0448); high-dose -22.21% (p=0.0313)
QiShenYiQiPhase 2BotanicalTraditional Chinese medicine (multi-component)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 2Small moleculeVasopressin V2 receptornot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 63 furthest-along competitors are listed; 36 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Injectafer / Ferinject (Ferric carboxymaltose) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 3Advanced Gastric CarcinomaRecruiting
Est. primary completion 2026-11-30 · NCT05226169 · CT.gov ↗
What to watch
December 2026 (2)
Phase 4Heart FailureRecruiting
Est. primary completion 2026-12 · NCT05793996 · CT.gov ↗
What to watch
Phase 4Myocardial Infarction, AcuteRecruiting
Est. primary completion 2026-12-31 · NCT05759078 · CT.gov ↗
What to watch
2027 (4)
August 2027 (1)
Phase 2/3Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent …Recruiting
Est. primary completion 2027-08-31 · NCT07217873 · CT.gov ↗
What to watch
September 2027 (1)
Phase 4Iron Deficiency AnemiaRecruiting
Est. primary completion 2027-09 · NCT06061393 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Iron Deficiency AnemiaNot yet recruiting
Est. primary completion 2027-11 · NCT07772453 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Surgery, Liver Metastases, Liver Cancer, Pancreas Cancer, Aortic AneurysmRecruiting
Est. primary completion 2027-12-31 · NCT05744219 · CT.gov ↗
What to watch
2028 (5)
March 2028 (1)
Early phase / not applicableIron Deficiency AnemiaNot yet recruiting
Est. primary completion 2028-03-01 · NCT07721519 · CT.gov ↗
What to watch
April 2028 (1)
Phase 4Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)Recruiting
Est. primary completion 2028-04 · NCT07476859 · CT.gov ↗
What to watch
June 2028 (1)
Phase 4Postpartum Depression (PPD)Recruiting
Est. primary completion 2028-06-22 · NCT06833788 · CT.gov ↗
What to watch
July 2028 (2)
Phase 4Aortic Valve Stenosis, Iron Deficiency, TAVI(Transcatheter Aortic Valve Implantation), Cardiovascular DiseasesRecruiting
Est. primary completion 2028-07 · NCT07370688 · CT.gov ↗
What to watch
Phase 4Pulmonary Hypertension, Iron DeficiencyRecruiting
Est. primary completion 2028-07 · NCT07359599 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
Phase 2Restless Legs Syndrome (RLS)Not yet recruiting
Est. primary completion 2029-04 · NCT07822607 · CT.gov ↗
What to watch

See the full readout calendar ↗